IgA肾病与膜性肾病患者肠道微生物菌群结构分析

【背景】越来越多的证据表明肠道失衡与免疫介导的疾病相关,但肠道菌群和免疫介导的肾脏疾病之间的关系仍不清楚。【目的】通过Illumina高通量测序方法对IgA肾病(immunoglobulin A nephropathy, IgAN)、膜性肾病(membranous nephropathy, MN)患者和健康人群的肠道菌群进行比较。【方法】回顾性选择2020年9月–2021年12月期间,在甘肃省人民医院肾内科行肾穿刺活检并诊断为IgAN及MN患者的新鲜粪便标本,分别编号为IgAN组和MN组,收集体检中心健康人群粪便标本作为健康对照组,每组样本为10例。采用高通量测序技术对粪便样本中所有细菌的16S rRNA基因V3-V4区进行DNA测序,然后进行分类操作单元(operational taxonomic units, OTU)、物种分类、α多样性、β多样性等分析,比较3组之间的肠道菌群差异。【结果】与健康对照组相比,门水平上IgAN组的变形菌门(Proteobacteria)和放线菌门(Actinobacteria)比例明显增高,分别为18%vs. 4%和18.3%vs. 5%;属水平上I...     

原发性IgA肾病与非IgA肾病生物化学鉴别诊断方法探索

目的: 研究探讨原发性IgA肾病和非IgA肾病的生物化学鉴别诊断方法。方法选取我院收治确诊为原发性IgA肾病和非IgA肾病且未经治疗的患者共60例作为研究对象。空腹状态下采集4ml静脉血标本,经处理后使用基质辅助激光解吸电离飞行时间质谱技术分别对患者的血清肽质量指纹图谱进行分析。结果: 经分析,原发性IgA肾病和非IgA肾病的血清肽质量指纹图谱有9个差异多肽,其中多肽峰5338是粘蛋白4同工型的片段,多肽峰2082是α1-Ⅱ型胶原同工型的片段。结论: 质谱的应用在肾病的诊断鉴别中有重要的意义,依据血清肽指纹图谱鉴别在IgA肾病和非IgA肾病的具有可行性。     

乙型肝炎肝硬化患者外周血单核细胞基因表达谱研究

目的 :探索基因表达谱技术在肝硬化形成的分子生物学机制研究及其诊断方法研究的应用。方法 :应用含 81 92个人体cDNA的微阵列芯片和来自外周血单核细胞的标记cDNA ,分析慢性乙型肝炎、肝炎肝硬化各 1 5例基因表达谱。通过GenePix40 0 0B扫描芯片仪和ImaGene3.0软件分析Cy3、Cy5两种荧光信号的强度和比值。结果 :在 81 92个基因中 ,2组中筛选出有差异的基因 60个 ,占 0 .73% ,其中主要是炎症、凋亡基因、细胞外基质蛋白基因、细胞生长调节基因 ,占 71 .6%。结论 :基因表达谱技术可为乙型肝炎肝硬化形成的分子生物学机制及其诊断研究提供大量有益的生物学信息     

乙型肝炎肝硬化患者外周血单核细胞基因表达谱研究

目的：探索基因表达谱技术在肝硬化形成的分子生物学机制研究及其诊断方法研究的应用。方法：应用含8192个人体cDNA的微阵列芯片和来自外周血单核细胞的标记cDNA,分析慢性乙型肝炎、肝炎肝硬化各15例基因表达谱。通过CenePix4000B扫描芯片仪和ImaGene3．0软件分析Cy3、Cy5两种荧光信号的强度和比值。结果：在8192个基因中,2组中筛选出有差异的基因60个,占0．73％,其中主要是炎症、凋亡基因、细胞外基质蛋白基因、细胞生长调节基因,占71．6％。结论：基因表达谱技术可为乙型肝炎肝硬化形成的分子生物学机制及其诊断研究提供大量有益的生物学信息。     

IgA肾病患者与健康人肠道菌群的比较

目的通过16S rRNA高通量基因测序方法对IgA肾病患者与健康人的肠道菌群进行比较。方法纳入生活于同一地区的40例IgA肾病患者与10例健康人,收集研究对象的新鲜粪便样本,提取粪便细菌总DNA,通过PCR扩增后上机测序,然后进行可操作分类单元聚类、物种分类分析及Alpha多样性分析、Beta多样性分析,最后比较两组之间的肠道菌群差异。结果与健康人相比,IgA肾病患者肠道菌群丰富度指数(Ace、Chao1)下降(u=2.308,P=0.033;u=2.259,P=0.039),多样性指数(Shannon、Simpson)升高(u=5.370,P0.001;u=4.601,P=0.007);相对丰度方面,IgA肾病患者的厚壁菌门、拟杆菌门、放线菌门细菌数量增加(t=2.301,P=0.037;t=6.729,P=0.005;t=5.285,P=0.006),而变形菌门细菌数量减少(t=4.138,P=0.009);拟杆菌属、链球菌属细菌数量增加(t=9.037,P=0.003;t=6.001,P=0.008),而unidentified_Enterobacteriaceae数量减少(t=2.198,P=0.033)。PCoA图提示两组肠道菌群有显著差异。LDA差异贡献分析发现两组之间共有15个物种存在显著差异,其中造成显著差异影响力最大的5个物种依次是γ-变形菌纲、unidentified_Enterobacteriaceae、肠杆菌科、肠杆菌目、变形菌门(t=9.930,P=0.002;t=2.198,P=0.033;t=2.604,P=0.015;t=2.393,P=0.021;t=4.138,P=0.009),它们刚好落在同一个进化树上,在IgA肾病组的相对丰度显著降低。结论 IgA肾病患者存在肠道菌群失调,显著减少的肠杆菌科的未知属可能是IgA肾病的特征菌,其对机体免疫的影响及在IgA肾病发生发展中的作用尚不清楚,进一步研究可能为IgA肾病的防治提供新的靶点。     

IgA肾病患者肾小球系膜区沉积的IgA1来源的研究进展

IgA肾病(immunoglobulin A nephropathy,IgAN)危害极大,明确系膜区IgA1的来源对于阐明发病机制、探索新的诊疗手段具有重要意义。诸多研究报道显示IgAN患者血液中以及肾小球系膜区沉积的IgA是半乳糖缺失IgA1,目前比较公认IgAN是"免疫复合物引起的肾小球疾病"。有关IgAN患者IgA1的来源,传统观点是粘膜相关的淋巴组织中B淋巴细胞产生过多而"溢出"至血液,或者通过粘膜-骨髓轴引起骨髓浆细胞产生并分泌至循环血液。近年来非B细胞表达免疫球蛋白的报道,以及近期我们在体外原代肾小球系膜细胞中检测到IgA1的表达和分泌的初步研究,提示系膜细胞也可以产生IgA1,并可能参与了IgAN患者系膜区IgA1的沉积及IgAN的发病机制。本文我们将围绕IgAN患者IgA1的来源进行综述。     

IgA肾病预后的相关影响因素分析

目的：分析IgA肾病预后的相关影响因素,为[gA肾病的治疗提供可靠的依据。方法：选择我市三家医院经病理确诊的143例IgA肾病患者,记录其临床资料,根据随访结果将患者的预后分为优、良、中、差4个档次,通过单因素、多因素等方法获得IgA肾病预后的影响因素。结果：1．LEE氏病理组织学分级是[gA肾病患者预后的危险因素,分级越高预后越差,P〈0．01。2．单因素分析：年龄、病程、高血压、尿蛋白含量、水肿程度、肉眼血尿均为其危险因素,ACEI治疗为其保护因素,P〈0．01。3．多因素分析显示尿蛋白含量、LEE肾组织学分级、病程、高血压及ACEI治疗纳入的累计概率模型有统计学意义。结论：尿蛋白含量、LEE肾组织学分级、病程、高血压是IgA肾病预后的危险因素,ACEI治疗是其保护因素。     

孢素联合糖皮质激素对IgA肾病患者IgA、C3及IgA/C3影响研究

目的:探讨孢素联合糖皮质激素对IgA肾病患者IgA、C3及IgA/C3的影响。方法:我院收治的IgA肾病住院患者90例,按用药不同分为对照组与实验组。对照组予以醋酸泼尼松片口服,实验组在对照组基础上予以予环孢素软胶囊口服,治疗结束后对患者的血肌酐、血尿酸、24 h尿蛋白定量及IgA、C3、IgA/C3进行检测。结果:与对照组相比,实验组24 h尿蛋白定量水平较低,P0.05;IgA水平及IgA/C3水平较低,P0.05,差异具有统计学意义;两组患者的C3、血肌酐、血尿酸水平无显著差异,无统计学意义(P0.05)。结论:孢素联合糖皮质激素能够显著降低Ig A肾病患者Ig A水平及IgA/C3,对C3水平无影响,对临床有指导意义。     

哮喘患者外周血单核细胞血红素氧合酶-1表达水平的研究

目的探讨血红素氧合酶-1(HO-1)在哮喘患者外周血单核细胞(PBMC)的表达及与肺通气功能的关系.方法应用免疫组织化学和逆转录聚合酶链反应技术分析18例哮喘患者PBMC的 HO-1蛋白及mRNA水平的表达,测定全血一氧化碳血红蛋白(COHb)的百分比含量、血清总IgE含量、肺通气功能,并与18名健康正常者的结果进行比较.结果哮喘组PBMC中HO-1表达阳性的细胞百分比41.7%±7.44%与正常对照组10.5%±4.36%比较,差异有显著性(P<0.01),哮喘组PBMC HO-1 mRNA表达的平均吸光度值(26.05±4.14)与正常对照组(10.82±4.26)比较,差异亦有显著性(P<0.01),HO-1染色阳性细胞的百分比与FEV1占预计值%、PEFR和MEFR50%均呈显著负相关(r值分别为-0.89,-0.56,-0.51,均P<0.01),与全血COHb的百分比含量及血清总IgE含量呈显著正相关(r值分别为0.80, 0.48, 均P<0.05).HO-1 mRNA的表达水平与1s用力呼气容积(FEV1)占预计值%、顶峰呼气流速(PEFR)和50%肺活量时的最大呼气流速(MEFR50%)均呈显著负相关(r 值分别为-0.89,-0.65,-0.67, 均P<0.01),与全血COHb的百分比含量和血清总IgE含量呈显著正相关(r分别为 0.85和0.62, 均P＜0.01).结论哮喘患者PBMC 的HO-1表达水平显著增加,提示HO-1可能参与了哮喘的发病过程,HO-1表达的变化与哮喘患者的病情程度有一定关系.     

家族性高胆固醇血症HDL-miRNAs调节血单核细胞功能机制

本研究通过生物信息学方法分析家族性高胆固醇血症患者外周血单核细胞差异表达基因、HDL载体差异表达miRNA及其生物学功能,研究差异HDL-miRNA与单核细胞差异基因的相关性,探讨HDL-miRNA调控外周血单核细胞功能机制,寻找动脉粥样硬化防治新靶点。运用R语言分析GEO数据库共享平台家族性高胆固醇血症外周血单核细胞基因及HDL-miRNA探针芯片得到差异基因及差异miRNA,利用miRwalk2. 0预测miRNA靶基因,并利用STRING进行蛋白互作分析,构建差异miRNA与差异基因之间的调控网络。运用GO及KEGG分析研究基因功能。利用GEO数据(GSE6054)筛选出834个差异表达基因,利用GEO数据(GSE25108)筛选出HDL上差异miRNA28个。交叉匹配得到由19个差异miRNA和56个差异基因组配对的74对miRNA-靶基因。GO富集分析56个差异基因主要富集于肾上腺素受体信号等分子功能。KEGG分析56个差异基因主要富集于造血谱系通路上。家族性高胆固醇血症差异HDL-miRNA与外周血单核细胞差异mRNA具有相关性,HDL-miRNA有通过调控血单核细胞功能的可能性,可能参与高胆固醇血症导致动脉粥样硬化过程。     

Aberrant glycosylation of IgA from patients with IgA nephropathy

Despite the prominent role of IgA, particularly IgA₁, in the pathogenesis of IgA nephropathy (IgAN), the precise role of this molecule in the process remains unclear. Four biotin-conjugated lectins in sandwich-type enzyme-linked immunosorbent assays were devised to determine the glycosylation profiles of total IgA and its subclasses. We took advantage of differential binding properties of these lectins to sugar residues to dissect the oligosaccharide chainsO-linked to the hinge and thoseN-linked to the Fc region of total IgA and IgA subclasses in 47 patients with IgAN and an equal number of controls. The proportion of sialylated IgA₁ was higher in patients compared with controls (p<0.02), whereas IgA₂ in patients appeared less well sialylated. A reduction of galactose in pathological IgA as detected by RCA-I became significant after treatment of the molecule with neuraminidase (p<0.01). Defective galactosylation was also observed for patient IgA₁ when it was probed with ECL, a lectin that has a specificity for Gal 1,4N-acetylglucosamine groupings onN-linked oligosaccharides. The RCA and ECL results, therefore, suggest that increased sialylation on the IgA₁ is onO-linked oligosaccharides in the hinge region. This was partly confirmed by a small increase in the binding of PNA to IgA₁ from the patient group. This lectin binds preferentially to Gal 1,3N-acetylgalactosamine groups that are found onO-linked oligosaccharides.     

Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy

To identify biomarker candidates associated with early IgA nephropathy (IgAN) and thin basement membrane nephropathy (TBMN), the most common causes presenting isolated hematuria in childhood, a proteomic approach of urinary exosomes from early IgAN and TBMN patients was introduced. The proteomic results from the patients were compared with a normal group to understand the pathophysiological processes associated with these diseases at the protein level. The urinary exosomes, which reflect pathophysiological processes, collected from three groups of young adults (early IgAN, TBMN, and normal) were trypsin-digested using a gel-assisted protocol, and quantified by label-free LC-MS/MS, using an MS(E) mode. A total of 1877 urinary exosome proteins, including cytoplasmic, membrane, and vesicle trafficking proteins, were identified. Among the differentially expressed proteins, four proteins (aminopeptidase N, vasorin precursor, α-1-antitrypsin, and ceruloplasmin) were selected as biomarker candidates to differentiate early IgAN from TBMN. We confirmed the protein levels of the four biomarker candidates by semi-quantitative immunoblot analysis in urinary exosomes independently prepared from other patients, including older adult groups. Further clinical studies are needed to investigate the diagnostic and prognostic value of these urinary markers for early IgAN and TBMN. Taken together, this study showed the possibility of identifying biomarker candidates for human urinary diseases using urinary exosomes and might help to understand the pathophysiology of early IgAN and TBMN at the protein level.     

IgA肾病患者血液、尿液及咽拭子标本中穿通支原体的分离检出

目的探讨IgA肾病患者血液、尿液及咽拭子标本中穿通支原体（Mycoplasma penetrans,Mp）的分离检出率以及与病理型别相关性。方法采用分离培养法,共计从26例IgA肾病患者血液、尿液及咽拭子标本及38例正常对照相应标本中进行穿通支原体分离检测,对培养阳性标本用穿通支原体套式PCR进行证实。结果在11例（42．3％）患者血液与尿液或（和）咽拭子中同时分离到穿通支原体,单独尿液或咽拭子标本阳性分别为1例（3．8％）与7例（26．9％）。26例IgA肾病患者血液、尿液及咽拭子穿通支原体的分离检出率分别为42．3％、23．1％与57．7％;与38例正常对照组血液、尿液及咽拭子检出0例、2例（5．3％）与7例（18．4％）相比较,差异有非常显著性（P〈0．01）,在正常对照组中无2种以上标本同时检出穿通支原体。结论穿通支原体在ISA肾病患者的血液、尿液与咽拭子标本中均有较高的检出率且与病理型别有一定的相关性。     

Difference in IgA1 O-glycosylation between IgA deposition donors and IgA nephropathy recipients

IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis, and disease recurrence often occurs after transplantation. On the other hands, Asymptomatic IgA deposition (IgAD) is occasionally observed in donated kidney. It is recognized that IgAD does not progress to IgAN, but the mechanism has not demonstrated yet. In IgAN, aberrant IgA1 O-glycan structure in the hinge region (HR) of serum IgA is suggested as one of the most convincing key mediators. However, little is known about IgA1 O-glycan structure in IgAD patients. Herein, we investigated the prevalence of IgAD in living renal transplant donors in our cohort. IgAD was observed in 21(13.0%) among 161 renal transplant donors and have statistically significant blood relationship with IgAN recipients (28.6% in relatives vs. 9.8% in non-relatives, respectively; p?=?0.0073). Next, we evaluated the IgA1 O-glycan structure of serum IgA from IgAN recipients (n?=?26), IgAD donors (n?=?17), and non-IgAD helthy donors (n?=?27) using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI–TOF MS). The numbers of GalNAc and Gal and the Gal/GalNAc ratio in the HR of the IgAN recipients had significantly lower comparing to the IgAD and non-IgAD healthy donors. The decreased Gal/GalNAc ratio in IgAN recipients means the increased ratio of galactose-deficient IgA1. To the best of our knowledge, this is the first report to compare the O-glycan structures in IgAN recipients and IgAD donors using MALDI–TOF MS. We concluded that IgAD was more common in IgAN related donors. Overall, decreased GalNAc and Gal contents in HR could play a material pathogenic role in IgAN.     

Identification of interleukin-13 related biomarkers using peripheral blood mononuclear cells

Asthma is a chronic disorder characterized by airway inflammation, reversible bronchial obstruction, hyper-responsiveness and remodelling. Data from human in vitro studies and experimental in vivo models of asthma has implicated interleukin (IL)-13 in the asthma phenotype suggesting that a therapeutic agent against it could be effective in treating asthma. The role of biomarkers is becoming increasingly important in the clinical development of therapeutics. Here we describe the use of the GeneChip^® DNA microarray technology platform to explore and identify potential response to therapy biomarkers that are associated with the biology of IL-13. Peripheral blood mononuclear cells (PBMCs) from eight healthy donors were cultured in the presence of IL-13, IL-4, an anti-IL-13 monoclonal antibody (mAb) or an isotype control mAb, and RNA from the treated cells was subjected to microarray analysis. The results revealed a number of genes, such as CCL17 (TARC), CCL22 (MDC), CCL23 (MPIF-1), CCL26 (eotaxin 3) and WNT5A (human wingless-type MMTV integration site family member 5A), that showed increased expression in the IL-13 and IL-4 treatment groups. Real-time polymerase chain reaction (PCR) subsequently confirmed these results. A follow-up study in PBMCs from five additional healthy donors showed that the neutralization of IL-13 completely blocked IL-13-induced TARC, MDC and eotaxin 3 production at the protein level. These data suggest that TARC, MDC, eotaxin 3, CCL23 and WNT5A if validated could serve as potential biomarkers for anti-IL-13 therapeutics.     

Identification of interleukin-13 related biomarkers using peripheral blood mononuclear cells

Asthma is a chronic disorder characterized by airway inflammation, reversible bronchial obstruction, hyper-responsiveness and remodelling. Data from human in vitro studies and experimental in vivo models of asthma has implicated interleukin (IL)-13 in the asthma phenotype suggesting that a therapeutic agent against it could be effective in treating asthma. The role of biomarkers is becoming increasingly important in the clinical development of therapeutics. Here we describe the use of the GeneChip^® DNA microarray technology platform to explore and identify potential response to therapy biomarkers that are associated with the biology of IL-13. Peripheral blood mononuclear cells (PBMCs) from eight healthy donors were cultured in the presence of IL-13, IL-4, an anti-IL-13 monoclonal antibody (mAb) or an isotype control mAb, and RNA from the treated cells was subjected to microarray analysis. The results revealed a number of genes, such as CCL17 (TARC), CCL22 (MDC), CCL23 (MPIF-1), CCL26 (eotaxin 3) and WNT5A (human wingless-type MMTV integration site family member 5A), that showed increased expression in the IL-13 and IL-4 treatment groups. Real-time polymerase chain reaction (PCR) subsequently confirmed these results. A follow-up study in PBMCs from five additional healthy donors showed that the neutralization of IL-13 completely blocked IL-13-induced TARC, MDC and eotaxin 3 production at the protein level. These data suggest that TARC, MDC, eotaxin 3, CCL23 and WNT5A if validated could serve as potential biomarkers for anti-IL-13 therapeutics.     

Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients

This study was performed to determine whether immunoreactivity of intrarenal hemeoxygenase-1 and angiotensinogen are increased in IgA nephropathy (IgAN) patients. Hemeoxygenase-1 and angiotensinogen immunoreactivity were determined by immunohistochemistry robot system in renal specimens from 39 patients with IgAN. Normal portions of surgically resected kidney served as controls. IgAN patients showed moderate proteinuria (1.1+/-0.2 g/day); however, the control group did not show any proteinuria. Immunoreactivity of intrarenal hemeoxygenase-1 and angiotensinogen in IgAN were significantly increased compared to normal kidneys (2.42+/-0.42 vs 1.00+/-0.26 for hemeoxygenase-1 and 4.05+/-0.40 vs 1.00+/-0.21 for angiotensinogen, arbitrary unit). Even though these IgAN patients did not show massive renal damage, hemeoxygenase-1 and angiotensinogen immunoreactivity were increased in these patients at this time point. These data suggest that activated intrarenal reactive oxygen species-angiotensinogen axis plays some roles in development of IgAN at the early stage and will provide supportive foundation of effectiveness of the renin-angiotensin system blockade in IgAN.